Empirical investigation has demonstrated a significant association between elevated CCL5 levels in tumor specimens and an augmented susceptibility to neoplasm relapse within a 5-year period following therapeutic intervention (Figure 2). This evidence concerns the gene CCL5 and neoplasm.